CYTOMX THERAPEUTICS INC
NASDAQ: CTMX (CytomX Therapeutics, Inc.)
Kemas kini terakhir: 28 minit lalu2.02
-0.02 (-1.23%)
| Penutupan Terdahulu | 2.04 |
| Jumlah Dagangan | 693,367 |
| Harga / Jualan (P/S) | 28.42 |
| Harga / Buku (P/B) | 1.55 |
| Julat 52 Minggu |
| Margin Keuntungan | 28.19% |
| Margin Operasi (TTM) | 44.43% |
| EPS Cair (TTM) | 0.480 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 22.80% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 70.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 32.53% |
| Nisbah Semasa (MRQ) | 1.73 |
| Aliran Tunai Operasi (OCF TTM) | -81.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -53.07 M |
| Pulangan Atas Aset (ROA TTM) | 15.87% |
Sentimen Berita
AISkor Stockmoo
| Nilai 30% | 3.4 |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Harga rendah berbanding pertumbuhan perolehannya. info | |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Hutang rendah. Keuntungan kukuh. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Pulangan atas Modal info | NA |
| Masa 30% | -4.0 |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Corak Lilin info | NA |
| Aliran bagi Tempoh Pegangan Anda info | NA |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini bercampur atau neutral. info | |
| Wang Pintar 20% | -0.7 |
| Aktiviti Orang Dalam info | NA |
| Institusi bersih -0.08% daripada saham dalam pemfailan 13F terkini: 114 pemegang menambah, 75 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat +35.0% dari 31 Aug hingga 30 Oct 2026, 12 hari untuk tutup (FINRA). info | |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak tidak sependapat, jadi skor dilemahkan. | |
| Tidak dikira dalam skor | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info | |
| Harga di antara sokongan dan rintangan. Paras sokongan dan rintangan menaik. info | |
| Skor Akhir | -0.30 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | CytomX Therapeutics, Inc. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| CTMX | - | - | - | 1.55 |
| OPT | 583 M | - | - | 4.31 |
| OCUP | 51 M | - | - | 0.870 |
| ZYME | - | - | - | 7.29 |
| PBYI | - | - | - | 2.73 |
| ORMP | - | 6.74% | - | 0.530 |
|
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.83% |
| % Dimiliki oleh Institusi | 47.10% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Elmind Capital, Lp | 30 Jun 2026 | 4,550,000 |
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 103.35%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 114 | 29,761,343 |
| Berkurang | 75 | 28,757,015 |
| Baharu | 46 | 5,112,628 |
| Dijual habis | 32 | 6,286,727 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 45,246,966 | 12.0 |
| 15 Oct 2026 | 42,790,446 | 13.8 |
| 30 Sep 2026 | 40,813,393 | 8.7 |
| 15 Sep 2026 | 38,639,220 | 9.3 |
| 31 Aug 2026 | 33,512,293 | 11.8 |
| 14 Aug 2026 | 34,619,999 | 15.9 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Nov 2026 | Yahoo Finance |
CytomX (CTMX) Q3 2026 Earnings Call Transcript
Lower diarrhea rates emerge, but toxicity control remains the key test. |
| 05 Nov 2026 | Yahoo Finance |
CytomX Therapeutics Q3 Earnings Call Highlights
CytomX Therapeutics (NASDAQ:CTMX) plans to provide a January update on its lead cancer drug candidate, Varseta-M, as it prepares for a potential registrational study in metastatic colorectal cancer in the first half of 2027. The update is expected to include the first look at overall survival data… |
| 05 Nov 2026 | Yahoo Finance |
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 0.00% and -59.68%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 05 Nov 2026 | Yahoo Finance |
CytomX Therapeutics: Q3 Earnings Snapshot
(AP) — SOUTH SAN FRANCISCO, Calif. (AP) — CytomX Therapeutics Inc. |
| 05 Nov 2026 | Yahoo Finance |
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase… |
| 02 Nov 2026 | Yahoo Finance |
CytomX Therapeutics to Present at Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in November. Guggenheim 3rd Annual… |
| 29 Oct 2026 | Yahoo Finance |
CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close of U.S.… |
| 01 Sep 2026 | Yahoo Finance |
CytomX Therapeutics to Present at Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. Wells Fargo 21st Annual… |
| 27 Aug 2026 | Yahoo Finance |
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 - SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc.… |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |